Author(s):
Neha Sharma, Sakshi Sharma, Madhu Bala, Ritesh Rana, Neelam Sharma
Email(s):
imnehavk@gmail.com
DOI:
10.52711/2321-5836.2024.00002 
Address:
Neha Sharma1*, Sakshi Sharma2, Madhu Bala1, Ritesh Rana1, Neelam Sharma1
1Department of Pharmaceutics, Himachal Institute of Pharmaceutical Education and Research, Nadaun, HP
2Department of Pharmaceutics, Chandigarh Engineering College, CGC, Jhanjeri Mohali
*Corresponding Author
Published In:
Volume - 16,
Issue - 1,
Year - 2024
ABSTRACT:
Manily the cases of monkeypox connected to the 2022 breakout are being reported in nations throughout Europe and the Western Hemisphere, where it was formerly endemic to parts of Africa. Numerous groups are working on contact-tracing initiatives, but it is still unclear what started this outbreak. The monkeypox virus disease is a zoonotic viruses is a member of the orthopoxvirus genus and belonging to family poxiviridae. Following the eradication of smallpox worldwide in the 1970s, occurrences of monkeypox attracted attention on a global scale. The monkeypox virus could be protected against by the smallpox vaccine. Monkeypox instances increased once the smallpox vaccine was no longer administered. Monkeypox did not really receive widespread notice until the 2003 US outbreak. Despite the name "monkeypox," the virus did not originate in monkeys. The virus has been linked to a numeral of rodents and small animals, but the exact source of monkeypox is still unknown. The viral infection was originally noticed in macaque monkeys, hence the term "monkeypox." Although transmission of monkeypox from person to person is extremely uncommon, it is frequently assign to respiratory secretions or closely contacted with mucocutaneous abrasion of the contaminated person. Now present no designated cure for contaminated person, although supportive therpy may be used to relieve symptoms; in extremely severe cases, medications such tecovirimat may be used. Because there are no precise recommendations for symptom alleviation, many treatments are arbitrary. In light of the current outbreaks worldwide, we provide updated information on monkeypox for healthcare professionals in this review.
Cite this article:
Neha Sharma, Sakshi Sharma, Madhu Bala, Ritesh Rana, Neelam Sharma. A Comprehensive Review on the Transmission, Pathogenesis, and Prevention of Monkey Pox. Research Journal of Pharmacology and Pharmacodynamics. 2024;16(1):6-4. doi: 10.52711/2321-5836.2024.00002
Cite(Electronic):
Neha Sharma, Sakshi Sharma, Madhu Bala, Ritesh Rana, Neelam Sharma. A Comprehensive Review on the Transmission, Pathogenesis, and Prevention of Monkey Pox. Research Journal of Pharmacology and Pharmacodynamics. 2024;16(1):6-4. doi: 10.52711/2321-5836.2024.00002 Available on: https://rjppd.org/AbstractView.aspx?PID=2024-16-1-2
REFERENCES:
1. (ICTV) ICoToV. Virus Taxonomy: 2020 Release. Available from: https://talk.ictvonline.org/taxonomy
2. Fine PE, Jezek Z, Grab B, Dixon H. The transmission potential of monkeypox virus in human populations. International journal of epidemiology. 1988; 17(3):643-50.
3. Jezek Z, Khodakevich LN, Wickett JF. Smallpox and its post-eradication surveillance. Bulletin of the world health organization. 1987; 65(4):425.
4. Magnus PV, Andersen EK, Petersen KB, Birch‐Andersen A. A pox‐like disease in cynomolgus monkeys. Acta Pathologica Microbiologica Scandinavica. 1959: 46(2):156-76.
5. Breman JG, Kalisa-Ruti, Steniowski MV, Zanotto E, Gromyko AI, Arita I. Human monkeypox, 1970-79. Bull World Health Organ. 1980; 58(2):165-82. PMID: 6249508; PMCID: PMC2395797.
6. Centers for Disease Control and Prevention. Monkeypox. Available from: https://www.cdc.gov/ poxvirus/monkeypox/index.html
7. Public Health England. Monkeypox case confirmed in England 2019. Available from: https://www.gov. uk/government/news/monkeypox-case-confirmed-in-england .\
8. Howard CR, Fletcher NF. Emerging virus diseases: can we ever expect the unexpected?. Emerging Microbes and Infections. 2012 ; 1(1):1-9.
9. Yong SE, Ng OT, Ho ZJ, Mak TM, Marimuthu K, Vasoo S, Yeo TW, Ng YK, Cui L, Ferdous Z, Chia PY. Imported Monkeypox, Singapore. Emerging Infectious Diseases. 2020; 26(8):1826.
10. Woolhouse ME, Gowtage-Sequeria S. Host range and emerging and reemerging pathogens. Emerging infectious diseases. 2005 Dec; 11(12):1842.
11. Miller S, Selgelid MJ. Ethical and philosophical consideration of the dual-use dilemma in the biological sciences. Science and Engineering Ethics. 2007; 13:523-80.
12. Selgelid MJ, Weir L, Jackson R, Ramshaw I. The mousepox experience: an interview with Ronald Jackson and Ian Ramshaw on dual‐use research. EMBO Reports. 2010; 11(1):18-24.
13. Evans NG. Dual-use decision making: relational and positional issues. Monash Bioethics Review. 2014; 32:268-83..
14. Webster RG. Mammalian-transmissible H5N1 influenza: the dilemma of dual-use research. MBio. 2012 Mar 1; 3(1):e00005-12.
15. MacNeil A, Reynolds MG, Braden Z, Carroll DS, Bostik V, Karem K, Smith SK, Davidson W, Li Y, Moundeli A, Mombouli JV. Transmission of atypical varicella-zoster virus infections involving palm and sole manifestations in an area with monkeypox endemicity. Clinical Infectious Diseases. 2009; 48(1):e6-8.
16. Mazurkov OY, Kabanov AS, Shishkina LN, Sergeev AA, Skarnovich MO, Bormotov NI, Skarnovich MA, Ovchinnikova AS, Titova KA, Galahova DO, Bulychev LE. New effective chemically synthesized anti-smallpox compound NIOCH-14. Journal of General Virology. 2016; 97(5):1229-39.
17. Reed KD, Melski JW, Graham MB, Regnery RL, Sotir MJ, Wegner MV, Kazmierczak JJ, Stratman EJ, Li Y, Fairley JA, Swain GR. The detection of monkeypox in humans in the Western Hemisphere. New England Journal of Medicine. 2004; 350(4):342-50.
18. Favier AL, Flusin O, Lepreux S, Fleury H, Labrèze C, Georges A, Crance JM, Boralevi F. Necrotic ulcerated lesion in a young boy caused by cowpox virus infection. Case Reports in Dermatology. 2011; 3(3):186-94.
19. Formenty P, Muntasir MO, Damon I, Chowdhary V, Opoka ML, Monimart C, Mutasim EM, Manuguerra JC, Davidson WB, Karem KL, Cabeza J. Human monkeypox outbreak caused by novel virus belonging to Congo Basin clade, Sudan, 2005. Emerging Infectious Diseases. 2010; 16(10):1539.
20. Kugelman JR, Johnston SC, Mulembakani PM, Kisalu N, Lee MS, Koroleva G, McCarthy SE, Gestole MC, Wolfe ND, Fair JN, Schneider BS. Genomic variability of monkeypox virus among humans, Democratic Republic of the Congo. Emerging infectious Diseases. 2014; 20(2):232.
21. Lefkowitz EJ, Wang C, Upton C. Poxviruses: past, present and future. Virus Research. 2006; 117(1):105-18.
22. Van Regenmortel MH, Fauquest CM, Bishop DH, Carstens EB, Estes MK, Lemon SM, Maniloff J, Mayo MA, McGoech DJ, Pringle CR, Wickner RB. Virus Taxonomy. Academic Press; San Diego: 2000.
23. Van Regenmortel MH. Virus taxonomy. Classification and nomenclature of viruses. Seventh report of the International Committee on Taxonomy of Viruses. 2000:395-480.
24. Poxviridae. ICTV 9th report (2011) International Committee on Taxonomy of Viruses.https://talk.ictvonline.org/ictv reports/ictv_9th_report/dsdna viruses 2011/w/dsdna_viruses/74/poxviridae. Accessed 27 August 2018).
25. Iyer LM, Aravind L, Koonin EV. Common origin of four diverse families of large eukaryotic DNA viruses. J Virol. 2001; 75:11720–11734.
26. Iyer LM, Balaji S, Koonin EV, Aravind L. Evolutionary genomics of nucleo-cytoplasmic large DNA viruses. Virus Research. 2006; 117:156–184.
27. Sklenovská, N. (2020). Monkeypox Virus. Livestock Diseases and Management, 39 68 https://doi.org/10.1007/978-981-15-2651-0_2
28. World Health Organization. Monkeypox 2019 [updated December 9, 2019]. Available from: https://www.who.int/news-room/fact-sheets/detail/monkeypox
29. World Health Organization (16 May 2022). Disease Outbreak News; Monkeypox– United Kingdom of Great Britain and Northern Ireland. Available at: https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON381
30. World Health Organization (18 May 2022). Disease Outbreak News; Monkeypox– United Kingdom of Great Britain and Northern Ireland. Available at: https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON383
31. Meyer H, Perrichot M, Stemmler M, et al. Outbreaks of disease suspected of be- ing due to human monkeypox virus infection in the Democratic Republic of Congo in 2001. J Clin Microbiol 2002; 40:2919–21. doi:10.1128/JCM.40.8. 2919-2921.2002
32. Khodakevich L, Jezek Z, Kinzanzka K. Isolation of monkeypox virus from wild squirrel infected in nature. Lancet. 1986; 1:98–9. doi:10.1016/S0140-6736(86) 90748-8
33. Radonić A, Metzger S, Dabrowski PW, et al. Fatal monkeypox in wild-living sooty mangabey, Côte d’Ivoire, 2012. Emerg Infect Dis 2014; 20:1009–11. doi: 10.3201/eid2006.131329
34. Patrono LV, Pléh K, Samuni L, et al. Monkeypox virus emergence in wild chim- panzees reveals distinct clinical outcomes and viral diversity. Nat Microbiol 2020; 5:955–65. doi:10.1038/s41564-020-0706-0
35. Falendysz EA, Lopera JG, Doty JB, et al. Characterization of monkeypox virus infection in African rope squirrels (funisciurus sp.). PLoS Negl Trop Dis 2017; 11:e0005809. doi:10.1371/journal.pntd.0005809
36. Doty JB, Malekani JM, Kalemba LN, et al. Assessing monkeypox virus preva- lence in small mammals at the human-animal interface in the Democratic Republic of the Congo. Viruses 2017; 9:283. doi:10.3390/v9100283
37. Di Giulio DB, Eckburg PB. Human monkeypox: an emerging zoonosis. Lancet Infect Dis 2004; 4:15–25. doi:10.1016/S1473-3099(03)00856-9
38. Boghuma K Titanji, Bryan Tegomoh, Saman Nematollahi, Michael Konomos, Prathit A Kulkarni, Monkeypox: A Contemporary Review for Healthcare Professionals, Open Forum Infectious Diseases. 2022; 9(7)::310, https://doi.org/10.1093/ofid/ofac310
39. Moore M, Zahra F: Monkeypox. StatPearls [Internet], Treasure Island (FL); 2022.
40. Okyay RA, Bayrak E, Kaya E, et al.: Another epidemic in the shadow of Covid 19 pandemic: a review of monkeypox. EJMO. 2022, 6:95-9. 10.14744/ejmo.2022.2022
41. Reynolds MG, McCollum AM, Nguete B, Shongo Lushima R, Petersen BW: Improving the care and treatment of monkeypox patients in low-resource settings: applying evidence from contemporary biomedical and smallpox biodefense research. Viruses. 2017, 9:380. 10.3390/v9120380
42. McCollum AM, Damon IK: Human monkeypox. Clin Infect Dis. 2014, 58:260-7. 10.1093/cid/cit703
43. Afshar ZM, Rostami HN, Hosseinzadeh R, et al.: The reemergence of monkeypox as a new potential health challenge: a critical review. Ann Med Surg. 2022, 78:
44. Stagles MJ, Watson AA, Boyd JF, et al.: The histopathology and electron microscopy of a human monkeypox lesion. Trans R Soc Trop Med Hyg. 1985, 79:192-202. 10.1016/0035-9203(85)90333-5
45. Patel AR, Romanelli P, Roberts B, Kirsner RS: Herpes simplex virus: a histopathologic study of the depth of herpetic wounds. Int J Dermatol. 2009, 48:36-40. 10.1111/j.1365-4632.2009.03788.x
46. Bunge EM, Hoet B, Chen L, et al. The changing epidemiology of human monkeypox-a potential threat? A systematic review. PLoS Negl Trop Dis 2022; 16:e0010141. doi:10.1371/journal.pntd.0010141
47. Centers of Disease Control and Prevention. Biosafety in Microbiological and Biomedical Laboratories. Editors PJ Meechan and J Potts). 6th ed. Available at: https://www.cdc.gov/labs/pdf/CDC-BiosafetyMicrobiologicalBiomedicalLaboratories- 2020-P.pdf. Accessed 17 June 2022.
48. Hammarlund E, Lewis MW, Carter SV, et al. Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. Nat Med 2005; 11:1005–11. doi:10.1038/nm1273
49. Grosenbach DW, Honeychurch K, Rose EA, et al. Oral tecovirimat for the treat- ment of smallpox. N Engl J Med 2018; 379:44–53. doi:10.1056/NEJMoa1705688
50. Wittek R. Vaccinia immune globulin: current policies, preparedness, and prod- uct safety and efficacy. Int J Infect Dis 2006; 10:193–201. doi:10.1016/j.ijid.2005. 12.001
51. James JS. Cidofovir recommended for approval for CMV retinitis. AIDS Treat News 1996; (no 244):6–7.
52. Lederman ER, Davidson W, Groff HL, et al. Progressive vaccinia: case descrip- tion and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. J Infect Dis 2012; 206:1372–85. doi:10.1093/infdis/jis510
53. US Food and Drug Administration. FDA approves the first drug with an indica- tion for treatment of smallpox. Rockville, MD: US Food and Drug Administration; July 13, 2018 (News Release). Available at: https://www.fda.gov/ news-events/press-announcements/fda-approves-first-drug-indication-treatment- smallpox. Accessed 15 June 2022.
54. Centers for Disease Control and Prevention. Guidance for Tecovirimat Use Under Expanded Access Investigational New Drug Protocol during 2022 U.S. Monkeypox Cases. Available at: https://www.cdc.gov/poxvirus/monkeypox/ clinicians/Tecovirimat.html. Accessed 15 June 2022.
55. US Food and Drug Administration. FDA approves drug to treat smallpox. Rockville, MD: US Food and Drug Administration; June 4, 2021 (News Release). Available at: https://www.fda.gov/drugs/news-events-human-drugs/ fda-approves-drug-treat-smallpox. Accessed 15 June 2022.
56. CIDRAP. FDA approves VIG for smallpox shot complications. Available at: https://www.cidrap.umn.edu/news-perspective/2005/02/fda-approves-vig-smallpox- shot-complications. Accessed 16 June 2022.
57. Centers for Disease Control and Prevention. Monkeypox and smallpox vaccine guidance. Accessed June 9, 2022. https://www.cdc.gov/poxvirus/monkeypox/clinicians/smallpox-vaccine.html
58. Rimoin AW, Mulembakani PM, Johnston SC, et al. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A. 2010; 107(37):16262-16267. doi:10.1073/pnas.1005769107PubMedGoogle ScholarCrossref
59. Guidelines on core components of infection prevention and control programmes at the national and acute health care facility level. Geneva: Health Organization; 2016 (https://apps.who.int/iris/handle/10665/251730, accessed 9 June 2022)